Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

4

Revenue 2017

Herceptin

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Herceptin was produced by Roche.

Biocon backs away from biosimilar filings in Europe

Biocon backs away from biosimilar filings in Europe EMA asks biotech to withdraw Herceptin and Neulasta biosimilar filings. Indian biotech Biocon has said its plan to launch two new biosimilars in Europe has been stymied by issues at its ... Sales of Herceptin were around $7bn last year, while Amgen

Ocrevus off to a flying start as Roche raises 2017 forecasts

Ocrevus off to a flying start as Roche raises 2017 forecasts Roche's mainstay biologic cancer therapies also held up well in the face of biosimilar competition in some markets, with Herceptin (trastuzumab) and MabThera/Rituxan (rituximab) both gaining 3% to

FDA panel backs Avastin and Herceptin biosimilars

FDA panel backs Avastin and Herceptin biosimilars A decision from the US regulator is expected in September. A US FDA advisory committee gave its blessing to two biosimilar versions of Roche's cancer antibodies Avastin and Herceptin yesterday, ... Meanwhile, sales of HER2-positive breast cancer therapy

Standing out in a crowd

Standing out in a crowd Celltrion’s Herceptin biosimilar - branded as Herzuma, it was submitted to the EMA for approval in November last year. ... versions of MabThera and Herceptin.

NICE relents on Kadcyla after Roche pricing negotiations

NICE relents on Kadcyla after Roche pricing negotiations older HER2-targeting drug Herceptin (trastuzumab) with capecitabine that has latterly become the standard treatment for advanced HER2-positive breast cancer.

[ Previous 5 results ] 9 10 11 12 13 14 15 16 17 18 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics